Edition:
United States

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

29.42USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$29.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
80,835
52-wk High
$37.45
52-wk Low
$22.10

Latest Key Developments (Source: Significant Developments)

Revance Therapeutics, Mylan Ireland Enter Collaboration Deal‍
Wednesday, 28 Feb 2018 04:17pm EST 

Feb 28 (Reuters) - Revance Therapeutics Inc <>::REVANCE THERAPEUTICS SAYS ‍CO, MYLAN IRELAND LIMITED ENTERED INTO COLLABORATION DEAL- SEC FILING​.REVANCE THERAPEUTICS - ‍MYLAN AGREED TO PAY CO NON-REFUNDABLE UPFRONT PAYMENT OF $25 MILLION WITH CONTINGENT PAYMENTS OF UP TO $100 MILLION.REVANCE THERAPEUTICS - ‍CONTINGENT PAYMENTS BASED UPON ACHIEVEMENT OF SPECIFIED MILESTONES, SPECIFIED, TIERED SALES MILESTONES OF UP TO $225 MILLION​.REVANCE THERAPEUTICS INC - ‍MYLAN WILL PAY REVANCE ROYALTIES ON SALES OF BIOSIMILAR IN MYLAN TERRITORIES​.REVANCE THERAPEUTICS - ‍MYLAN MAY ELECT TO HAVE DRUG PRODUCT MANUFACTURED BY ANOTHER PARTY.REVANCE THERAPEUTICS INC - CO GRANTED MYLAN EXCLUSIVE, LICENSE TO CO'S INTELLECTUAL PROPERTY RIGHTS FOR DEVELOPMENT, COMMERCIALIZATION OF BIOSIMILAR​.REVANCE THERAPEUTICS INC - CO WILL BE PRIMARILY RESPONSIBLE FOR NON-CLINICAL DEVELOPMENT ACTIVITIES, CLINICAL DEVELOPMENT ACTIVITIES IN N. AMERICA​.  Full Article

Revance Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $1.14
Wednesday, 28 Feb 2018 04:10pm EST 

Feb 28 (Reuters) - Revance Therapeutics Inc ::REVANCE RELEASES FOURTH QUARTER AND FULL YEAR 2017 RESULTS.REVANCE THERAPEUTICS INC - ‍REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018​.REVANCE THERAPEUTICS INC - QTRLY BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS $1.14.REVANCE THERAPEUTICS INC - ‍EXPECTS CASH BURN FOR 2018 TO BE IN RANGE OF $117 TO $137 MILLION​.  Full Article

Mylan To Bring Biosimilar Of Botox To Market Through Collaboration With Revance Therapeutics
Wednesday, 28 Feb 2018 04:05pm EST 

Feb 28 (Reuters) - Mylan Nv ::MYLAN TO BRING A BIOSIMILAR OF BOTOX TO THE MARKET THROUGH A COLLABORATION AND LICENSE AGREEMENT WITH REVANCE THERAPEUTICS.MYLAN NV - ‍COLLABORATION AND LICENSE DEAL FOR DEVELOPMENT AND COMMERCIALIZATION OF A PROPOSED BIOSIMILAR TO BOTOX​.MYLAN NV - ‍COLLABORATION INCLUDES AN UPFRONT PAYMENT OF $25 MILLION TO REVANCE​.MYLAN TO BRING A BIOSIMILAR OF BOTOX TO THE MARKET THROUGH A COLLABORATION AND LICENSE AGREEMENT WITH REVANCE THERAPEUTICS.  Full Article

Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Revance Therapeutics Inc ::REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS.REVANCE THERAPEUTICS INC - TRIAL'S PRIMARY ENDPOINT SHOWED ROBUST IMPACT ON PAIN, WITH GREATER THAN 50% REDUCTION FOR PATIENTS TREATED WITH RT002.REVANCE THERAPEUTICS INC - RT002 APPEARED TO BE GENERALLY SAFE AND WELL-TOLERATED THROUGH WEEK 8.REVANCE THERAPEUTICS - EXPECT TO CONDUCT ANOTHER PHASE 2A TRIAL WITH MODIFIED DESIGN TO DEMONSTRATE RT002'S ABILITY TO TREAT PLANTAR FASCIITIS.  Full Article

Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018
Thursday, 4 Jan 2018 08:30am EST 

Jan 4 (Reuters) - Revance Therapeutics Inc ::REVANCE PROVIDES UPDATE ON ANTICIPATED CLINICAL MILESTONES AND FINANCIAL OUTLOOK FOR 2018.REVANCE THERAPEUTICS INC - EXPECTS TO COMPLETE RT002 SAKURA PHASE 3 PROGRAM AND START RT002 PHASE 3 TRIAL FOR CERVICAL DYSTONIA IN 2018.REVANCE THERAPEUTICS INC - EXPECTS CASH BURN FOR 2018 TO BE IN RANGE OF $117 TO $137 MILLION.REVANCE THERAPEUTICS INC - ANTICIPATES 2018 GAAP RESEARCH AND DEVELOPMENT EXPENSE TO BE IN RANGE OF $84 TO $101 MILLION.  Full Article

Revance Announces Pricing Of Public Offering Of Common Stock
Thursday, 7 Dec 2017 08:30am EST 

Dec 7 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.REVANCE THERAPEUTICS INC - ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5.3 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $31.00 PER SHARE​.  Full Article

Revance Therapeutics Files For Potential Mixed Shelf Offering ‍​‍​
Tuesday, 5 Dec 2017 05:20pm EST 

Dec 5 (Reuters) - Revance Therapeutics Inc ::REVANCE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING ‍​‍​.  Full Article

Revance Announces Proposed Public Offering Of Common Stock
Tuesday, 5 Dec 2017 04:45pm EST 

Dec 5 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.REVANCE THERAPEUTICS INC - PROPOSED UNDERWRITTEN PUBLIC OFFERING IN WHICH IT WILL ISSUE AND SELL APPROXIMATELY $175 MILLION OF SHARES OF ITS COMMON STOCK.REVANCE THERAPEUTICS INC - CERTAIN STOCKHOLDERS OF CO ARE ALSO OFFERING 600,000 SHARES OF COMPANY'S COMMON STOCK FOR SALE TO PUBLIC.  Full Article

Revance’s RT002 Meets Primary, Secondary Endpoints In Sakura Phase 3 Trials
Tuesday, 5 Dec 2017 07:30am EST 

Dec 5 (Reuters) - Revance Therapeutics Inc ::REVANCE’S RT002 MEETS PRIMARY AND ALL SECONDARY ENDPOINTS, ACHIEVES 6-MONTH DURATION IN PIVOTAL SAKURA PHASE 3 TRIALS FOR GLABELLAR LINES.SAYS RT002 DELIVERED HIGHLY STATISTICALLY SIGNIFICANT REDUCTION IN SEVERITY OF GLABELLAR LINES AT WEEK 24.SAYS RT002 DELIVERED POSITIVE TOP-LINE RESULTS IN ALLEVIATING MODERATE-TO-SEVERE GLABELLAR LINES IN 2 PIVOTAL SAKURA PHASE 3 TRIALS.SAYS RT002 APPEARED GENERALLY SAFE AND WELL-TOLERATED IN BOTH STUDIES.SAYS ASSUMING SUCCESSFUL COMPLETION OF SAKURA 3, COMPANY PLANS TO SUBMIT A BIOLOGICS LICENSE APPLICATION IN FIRST HALF OF 2019.SAYS LONG-TERM SAFETY TRIAL, SAKURA 3, IS FULLY ENROLLED AND IS EXPECTED TO BE COMPLETED IN SECOND HALF OF 2018.SAYS COMPANY PLANS TO LAUNCH RT002 IN U.S. IN 2020, PENDING APPROVAL BY FDA.  Full Article

Revance Plans Phase 3 Program For RT002 Injectable To Treat Cervical Dystonia
Wednesday, 29 Nov 2017 04:05pm EST 

Nov 29 (Reuters) - Revance Therapeutics Inc ::REVANCE PLANS PHASE 3 PROGRAM FOR RT002 INJECTABLE TO TREAT CERVICAL DYSTONIA.REVANCE THERAPEUTICS INC - COMPANY COMPLETES END-OF-PHASE 2 MEETING WITH FDA.REVANCE THERAPEUTICS - FINALIZING TRIAL PROTOCOLS FOR PIVOTAL RT002 PROGRAM, WHICH IS PLANNED TO COMMENCE IN Q2 2018.  Full Article

BRIEF-Revance Reports Qtrly Loss Per Share $0.97

* REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018 Source text for Eikon: Further company coverage: